Cerevel Therapeutics Holdings Inc (CERE)
40.78
+0.14
(+0.34%)
USD |
NASDAQ |
May 31, 16:00
40.74
-0.04
(-0.10%)
Pre-Market: 20:00
Cerevel Therapeutics Holdings Free Cash Flow: -370.79M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -370.79M |
| December 31, 2023 | -346.11M |
| September 30, 2023 | -335.72M |
| June 30, 2023 | -343.15M |
| March 31, 2023 | -322.56M |
| December 31, 2022 | -297.14M |
| September 30, 2022 | -263.02M |
| Date | Value |
|---|---|
| June 30, 2022 | -227.41M |
| March 31, 2022 | -217.82M |
| December 31, 2021 | -189.05M |
| September 30, 2021 | -184.49M |
| June 30, 2021 | -166.90M |
| March 31, 2021 | -145.76M |
| December 31, 2020 | -136.69M |
Free Cash Flow Range, Past 5 Years
-370.79M
Minimum
Mar 2024
-136.69M
Maximum
Dec 2020
-253.33M
Average
-245.22M
Median
Free Cash Flow Benchmarks
| AbbVie Inc | 21.89B |
| Bristol-Myers Squibb Co | 12.51B |
| Madrigal Pharmaceuticals Inc | -391.12M |
| Viking Therapeutics Inc | -54.87M |
| Karuna Therapeutics Inc (DELISTED) | -388.74M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -119.67M |
| Cash from Investing (Quarterly) | 19.16M |
| Cash from Financing (Quarterly) | 4.475M |
| Free Cash Flow Per Share (Quarterly) | -0.6604 |
| Free Cash Flow Yield | -5.40% |